<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02215759</url>
  </required_header>
  <id_info>
    <org_study_id>1246.15</org_study_id>
    <nct_id>NCT02215759</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets (100 mg, 200 mg and 300 mg Three Times Every Two Hours on One Day and q.d. for Another 2 to 3 Days) in Healthy Male and Female Volunteers, a Randomised, Doubleblind, Placebo-controlled Within Dose Groups Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Evaluation of safety, tolerability and pharmacokinetics of multiple rising oral doses of BI&#xD;
      44370 TA in healthy male and female volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 36 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant findings in vital signs</measure>
    <time_frame>up to 7 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant findings in 12-lead ECG (electrocardiogram)</measure>
    <time_frame>up to 7 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant laboratory findings</measure>
    <time_frame>up to 7 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>up to 7 days after last drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax ) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to maximum measured concentration of the analyte in plasma (tmax) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of the AUC 0-∞ that is obtained by extrapolation (%AUCtz-∞) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant in plasma (λz) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after p.o. administration (MRTpo) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular administration (Vz/F) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of analyte that is eliminated in urine from zero to 24 h after drug administration (Ae0-24) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of analyte eliminated in urine from zero to 24 h after drug administration (fe0-24) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of the analyte from zero to 24 h after drug administration (CLR,0-24) for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RA) based on Cmax for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA based on AUC for several time points</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity index (LI) of the analyte in plasma</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 44370 TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 44370 TA</intervention_name>
    <arm_group_label>BI 44370 TA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females according to the following criteria based upon a complete&#xD;
             medical history, including the physical examination, vital signs, 12-lead ECG,&#xD;
             clinical laboratory tests&#xD;
&#xD;
          -  Age ≥21 and Age ≤50 year&#xD;
&#xD;
          -  BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including vital signs and ECG) deviating from&#xD;
             normal and of clinical relevance&#xD;
&#xD;
          -  Any evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy/hypersensitivity (including allergy to drug or its&#xD;
             excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less&#xD;
             than 10 half-lives of the respective drug prior to administration or during the trial&#xD;
&#xD;
          -  Use of drugs which might reasonably influence the results of the trial or that prolong&#xD;
             the QT/QTc interval based on the knowledge at the time of protocol preparation within&#xD;
             10 days prior to administration or during the trial&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within two months prior to&#xD;
             administration or during the trial&#xD;
&#xD;
          -  Smoking (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)&#xD;
&#xD;
          -  Inability to refrain from smoking on trial days&#xD;
&#xD;
          -  Alcohol abuse (more than 40 g/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation (more than 100 mL within four weeks prior to administration or during&#xD;
             the trial)&#xD;
&#xD;
          -  Excessive physical activities (within one week prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTc interval &gt;450 ms)&#xD;
&#xD;
          -  A history of additional risk factors for torsade de pointes (e.g., heart failure,&#xD;
             hypokalaemia, family history of Long QT Syndrome)&#xD;
&#xD;
        Exclusion criteria for male subjects are:&#xD;
&#xD;
          -  Not willing to use adequate contraception (condom plus another form of contraception&#xD;
             e.g. spermicide, oral contraceptive taken by female partner, sterilisation,&#xD;
             intrauterine device) during the whole study period from the time of the first intake&#xD;
             of study drug until three months after the last intake&#xD;
&#xD;
        Exclusion criteria for female subjects are:&#xD;
&#xD;
          -  Pregnancy or planning to become pregnant within 3 months of study completion&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  No adequate contraception, e.g. implants, injectables, combined oral contraceptives,&#xD;
             surgical sterilisation (including hysterectomy or bilateral ovariectomy), intrauterine&#xD;
             device, not having used an adequate method of contraception for at least three months&#xD;
             prior to participation in the study, and not willing or able to use such adequate&#xD;
             contraception until three months after the last intake of study drug&#xD;
&#xD;
          -  Lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02215759
org study id: 1246.15
nct id: NCT02215759
lead sponsor: 
Evaluation of safety, tolerability and pharmacokinetics of multiple rising oral doses of BI
      44370 TA in healthy male and female volunteers
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double
measure: Number of patients with adverse events
time frame: up to 36 days
measure: Number of patients with clinically relevant findings in vital signs
time frame: up to 7 days after last drug administration
measure: Number of patients with clinically relevant findings in 12-lead ECG (electrocardiogram)
time frame: up to 7 days after last drug administration
measure: Number of patients with clinically relevant laboratory findings
time frame: up to 7 days after last drug administration
measure: Assessment of tolerability by investigator on a 4-point scale
time frame: up to 7 days after last drug administration
measure: Maximum measured concentration of the analyte in plasma (Cmax ) for several time points
time frame: up to 4 days
measure: Time from dosing to maximum measured concentration of the analyte in plasma (tmax) for several time points
time frame: up to 4 days
measure: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC) for several time points
time frame: up to 4 days
measure: The percentage of the AUC 0-∞ that is obtained by extrapolation (%AUCtz-∞) for several time points
time frame: up to 4 days
measure: Terminal rate constant in plasma (λz) for several time points
time frame: up to 4 days
measure: Terminal half-life of the analyte in plasma (t1/2) for several time points
time frame: up to 4 days
measure: Mean residence time of the analyte in the body after p.o. administration (MRTpo) for several time points
time frame: up to 4 days
measure: Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for several time points
time frame: up to 4 days
measure: Apparent volume of distribution during the terminal phase λz following an extravascular administration (Vz/F) for several time points
time frame: up to 4 days
measure: Amount of analyte that is eliminated in urine from zero to 24 h after drug administration (Ae0-24) for several time points
time frame: up to 4 days
measure: Fraction of analyte eliminated in urine from zero to 24 h after drug administration (fe0-24) for several time points
time frame: up to 4 days
measure: Renal clearance of the analyte from zero to 24 h after drug administration (CLR,0-24) for several time points
time frame: up to 4 days
measure: Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
time frame: up to 4 days
measure: Accumulation ratio (RA) based on Cmax for several time points
time frame: up to 4 days
measure: RA based on AUC for several time points
time frame: up to 4 days
measure: Linearity index (LI) of the analyte in plasma
time frame: up to 4 days
arm group label: BI 44370 TA
arm group type: Experimental
arm group label: Placebo
arm group type: Placebo Comparator
intervention type: Drug
intervention name: BI 44370 TA
arm group label: BI 44370 TA
intervention type: Drug
intervention name: Placebo
arm group label: Placebo
criteria: 
gender: All
minimum age: 21 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com
description: Related Info
responsible party type: Sponsor